| 1 | 1 | | I |
|---|
| 2 | 2 | | 119THCONGRESS |
|---|
| 3 | 3 | | 1 |
|---|
| 4 | 4 | | STSESSION H. R. 796 |
|---|
| 5 | 5 | | To amend the Federal Food, Drug, and Cosmetic Act to require a warning |
|---|
| 6 | 6 | | label advising that the effects of mifepristone can be counteracted, to |
|---|
| 7 | 7 | | amend the Public Health Service Act to establish a hotline to provide |
|---|
| 8 | 8 | | information to women seeking to counteract the effects of mifepristone, |
|---|
| 9 | 9 | | and for other purposes. |
|---|
| 10 | 10 | | IN THE HOUSE OF REPRESENTATIVES |
|---|
| 11 | 11 | | JANUARY28, 2025 |
|---|
| 12 | 12 | | Mrs. M |
|---|
| 13 | 13 | | ILLERof Illinois (for herself, Mr. BABIN, Mr. MOOREof Alabama, Mr. |
|---|
| 14 | 14 | | M |
|---|
| 15 | 15 | | OOREof West Virginia, Mr. OGLES, Mr. WEBSTERof Florida, Ms. |
|---|
| 16 | 16 | | T |
|---|
| 17 | 17 | | ENNEY, Mr. CLYDE, Mr. HARRISof Maryland, and Mr. WEBERof |
|---|
| 18 | 18 | | Texas) introduced the following bill; which was referred to the Committee |
|---|
| 19 | 19 | | on Energy and Commerce |
|---|
| 20 | 20 | | A BILL |
|---|
| 21 | 21 | | To amend the Federal Food, Drug, and Cosmetic Act to |
|---|
| 22 | 22 | | require a warning label advising that the effects of |
|---|
| 23 | 23 | | mifepristone can be counteracted, to amend the Public |
|---|
| 24 | 24 | | Health Service Act to establish a hotline to provide infor- |
|---|
| 25 | 25 | | mation to women seeking to counteract the effects of |
|---|
| 26 | 26 | | mifepristone, and for other purposes. |
|---|
| 27 | 27 | | Be it enacted by the Senate and House of Representa-1 |
|---|
| 28 | 28 | | tives of the United States of America in Congress assembled, 2 |
|---|
| 29 | 29 | | VerDate Sep 11 2014 22:15 Feb 24, 2025 Jkt 059200 PO 00000 Frm 00001 Fmt 6652 Sfmt 6201 E:\BILLS\H796.IH H796 |
|---|
| 30 | 30 | | ssavage on LAPJG3WLY3PROD with BILLS 2 |
|---|
| 31 | 31 | | •HR 796 IH |
|---|
| 32 | 32 | | SECTION 1. SHORT TITLE. 1 |
|---|
| 33 | 33 | | This Act may be cited as the ‘‘Second Chance for 2 |
|---|
| 34 | 34 | | Moms Act of 2025’’. 3 |
|---|
| 35 | 35 | | SEC. 2. MIFEPRISTONE WARNING LABEL AND HOTLINE. 4 |
|---|
| 36 | 36 | | (a) W |
|---|
| 37 | 37 | | ARNINGLABEL.— 5 |
|---|
| 38 | 38 | | (1) I |
|---|
| 39 | 39 | | N GENERAL.—Section 502 of the Federal 6 |
|---|
| 40 | 40 | | Food, Drug, and Cosmetic Act (21 U.S.C. 352) is 7 |
|---|
| 41 | 41 | | amended by adding at the end the following: 8 |
|---|
| 42 | 42 | | ‘‘(hh) If it is the drug mifepristone, and its labeling 9 |
|---|
| 43 | 43 | | does not bear the following statement printed in con-10 |
|---|
| 44 | 44 | | spicuous text: ‘WARNING: Medical evidence suggests that 11 |
|---|
| 45 | 45 | | the abortifacient effects of mifepristone can be counter-12 |
|---|
| 46 | 46 | | acted by natural progesterone, which can increase the 13 |
|---|
| 47 | 47 | | chance of fetal survival. The American Society for Repro-14 |
|---|
| 48 | 48 | | ductive Medicine has determined that natural progester-15 |
|---|
| 49 | 49 | | one is safe in the first trimester of pregnancy. For more 16 |
|---|
| 50 | 50 | | information, call [lll].’ (with the blank filled in to 17 |
|---|
| 51 | 51 | | refer to the appropriate number for the hotline under sec-18 |
|---|
| 52 | 52 | | tion 1009 of the Public Health Service Act).’’. 19 |
|---|
| 53 | 53 | | (2) E |
|---|
| 54 | 54 | | FFECTIVE DATE.—Section 502(hh) of the 20 |
|---|
| 55 | 55 | | Federal Food, Drug, and Cosmetic Act (as added by 21 |
|---|
| 56 | 56 | | paragraph (1)) applies beginning on the date that is 22 |
|---|
| 57 | 57 | | 6 months after the date of enactment of this Act. 23 |
|---|
| 58 | 58 | | (b) H |
|---|
| 59 | 59 | | OTLINE.—Title X of the Public Health Service 24 |
|---|
| 60 | 60 | | Act (42 U.S.C. 300 et seq.) is amended by adding at the 25 |
|---|
| 61 | 61 | | end the following: 26 |
|---|
| 62 | 62 | | VerDate Sep 11 2014 22:15 Feb 24, 2025 Jkt 059200 PO 00000 Frm 00002 Fmt 6652 Sfmt 6201 E:\BILLS\H796.IH H796 |
|---|
| 63 | 63 | | ssavage on LAPJG3WLY3PROD with BILLS 3 |
|---|
| 64 | 64 | | •HR 796 IH |
|---|
| 65 | 65 | | ‘‘SEC. 1009. HOTLINE FOR REVERSAL OF EFFECTS OF 1 |
|---|
| 66 | 66 | | MIFEPRISTONE. 2 |
|---|
| 67 | 67 | | ‘‘(a) I |
|---|
| 68 | 68 | | NGENERAL.—The Secretary shall establish or 3 |
|---|
| 69 | 69 | | maintain, directly or by grant or contract, a toll-free hot-4 |
|---|
| 70 | 70 | | line to provide support for 24 hours a day, 7 days a week, 5 |
|---|
| 71 | 71 | | for women seeking to reverse the effects of the drug 6 |
|---|
| 72 | 72 | | mifepristone. 7 |
|---|
| 73 | 73 | | ‘‘(b) R |
|---|
| 74 | 74 | | EFERRALS TOAPR PROVIDERSONLY.—A re-8 |
|---|
| 75 | 75 | | ferral through the hotline described in subsection (a) may 9 |
|---|
| 76 | 76 | | only be made to a health care provider that provides abor-10 |
|---|
| 77 | 77 | | tion pill reversal services.’’. 11 |
|---|
| 78 | 78 | | Æ |
|---|
| 79 | 79 | | VerDate Sep 11 2014 22:15 Feb 24, 2025 Jkt 059200 PO 00000 Frm 00003 Fmt 6652 Sfmt 6301 E:\BILLS\H796.IH H796 |
|---|
| 80 | 80 | | ssavage on LAPJG3WLY3PROD with BILLS |
|---|